Maple Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) is the most potent synthetic growth hormone-releasing peptide characterized to date, distinguished from other GH secretagogues by its dual receptor engagement: GHS-R1a on pituitary somatotrophs for GH release, and CD36 scavenger receptors on cardiomyocytes for GH-independent cardioprotection. This dual pharmacology, confirmed through knockout mouse studies that dissected each receptor’s contribution, positions hexarelin as a uniquely bifunctional research tool in both neuroendocrine and cardiovascular investigation.
Structural Basis and GHRP-6 Lineage
Hexarelin belongs to the growth hormone-releasing peptide family, developed as a structural analog of GHRP-6 with a critical modification at position 2: substitution of D-Trp with D-2-methyl-Trp. This single methyl addition at the indole ring fundamentally altered the compound’s receptor binding profile. The resulting hexapeptide (molecular formula C47H58N12O6, molecular weight 887.04 g/mol, CAS 140703-51-1) demonstrates 10 to 20-fold greater binding affinity for GHS-R1a compared to native ghrelin, making it one of the highest-affinity synthetic ligands for this receptor class.
The structural modifications also conferred improved metabolic stability relative to GHRP-6. While GHRP-6 is rapidly degraded by serum peptidases, hexarelin’s methylated tryptophan residue provides steric protection against enzymatic cleavage at the N-terminal region. This translates to a more sustained receptor occupancy profile in preclinical pharmacokinetic studies, though the peptide still requires parenteral administration due to poor oral bioavailability characteristic of linear peptides in this size range.
GHS-R1a Mediated Growth Hormone Release
Hexarelin stimulates growth hormone secretion through direct activation of GHS-R1a (growth hormone secretagogue receptor type 1a) on anterior pituitary somatotrophs. Receptor binding triggers a Gq/11-coupled signaling cascade that activates phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG). The resulting intracellular calcium mobilization from endoplasmic reticulum stores, combined with extracellular calcium influx through voltage-gated channels, drives vesicular GH exocytosis.
What distinguishes hexarelin’s mechanism from GHRH-mediated GH release is the second messenger system involved. GHRH signals through Gs-coupled cAMP/PKA pathways, while hexarelin operates through the phospholipase C/calcium axis. This mechanistic independence explains the well-documented synergy between GHRPs and GHRH observed in co-administration studies, where combined treatment produces GH pulses substantially exceeding the additive effect of either stimulus alone.
A pivotal study by Arvat et al. (1997) in Peptides directly compared hexarelin and GHRP-2 effects on GH, prolactin, ACTH, and cortisol in six healthy adults aged 22 to 27 years. Both peptides produced comparable GH release exceeding that of GHRH alone, but notably, both also stimulated prolactin release (though less than TRH) and ACTH/cortisol secretion at magnitudes comparable to human corticotropin-releasing hormone (hCRH). This multi-hormone activation profile stands in contrast to ipamorelin, which selectively stimulates GH without significant cortisol or prolactin elevation, highlighting a key pharmacological trade-off: hexarelin’s superior GH-releasing potency comes at the cost of reduced receptor selectivity across pituitary cell populations.
In rat pituitary cell culture experiments, hexarelin at concentrations of 0.01 to 1 micromolar significantly stimulated GH release in both normal pituitary cells and GH1 cell lines insensitive to GHRH. At the 1 micromolar dose, GH release reached 155 +/- 25% of control in GH1 cells and 185 +/- 23% of control in normal rat pituitary cells. This activity in GHRH-resistant cells confirmed that hexarelin acts through a distinct receptor mechanism rather than potentiating GHRH signaling, providing early evidence for the existence of a dedicated GHS receptor that was later cloned and characterized as GHS-R1a.
CD36 Receptor Binding and GH-Independent Cardioprotection
The discovery that hexarelin binds CD36, a class B scavenger receptor expressed abundantly in cardiac tissue, fundamentally expanded the research significance of this peptide beyond neuroendocrinology. CD36 is an 88 kDa transmembrane glycoprotein expressed on cardiomyocytes, microvascular endothelial cells, macrophages, and adipocytes, with diverse roles in fatty acid transport, angiogenesis, and innate immunity.
Bhatt et al. published a landmark study in Circulation Research (2004) demonstrating that hexarelin’s cardioprotective effects were completely CD36-dependent and GHS-R1a-independent. Using CD36 knockout and GHS-R1a knockout mouse models subjected to ischemia-reperfusion injury, the researchers showed that hexarelin reduced infarct size by approximately 50% in wild-type mice. Critically, this protection was entirely abolished in CD36 knockout animals while fully preserved in GHS-R1a knockout mice. This experiment definitively dissected the two receptor pathways, proving that hexarelin’s cardiac effects operate through a mechanism completely separate from its growth hormone-releasing activity.
At the molecular level, hexarelin binding to CD36 activates several pro-survival signaling cascades. Downstream phosphorylation of PI3K/Akt promotes cell survival through inhibition of pro-apoptotic BAD and activation of eNOS for nitric oxide production. Concurrent ERK1/2 activation supports cellular stress resistance. The anti-apoptotic program includes upregulation of Bcl-2 expression and suppression of caspase-3 activity in cardiomyocytes subjected to ischemic stress. Photoaffinity cross-linking studies published in the Journal of Biological Chemistry mapped the hexarelin binding site on CD36 to a specific extracellular domain distinct from the fatty acid and thrombospondin binding regions, suggesting that hexarelin engagement does not compete with the receptor’s physiological ligands.
Preclinical Cardiac Fibrosis and Remodeling Data
McDonald et al. (2018) published a comprehensive study in Physiological Reports examining chronic hexarelin treatment in a mouse model of acute myocardial infarction induced by left coronary artery ligation. C57BL/6J mice received either vehicle or hexarelin at 0.3 mg/kg/day for 21 days post-infarction. Echocardiographic assessment at day 14 revealed significant improvement (p < 0.05) in left ventricular function in the hexarelin-treated group compared to vehicle controls. The end-diastolic volume increase observed 24 hours post-MI in vehicle-treated animals was completely reversed by hexarelin treatment at the 14-day timepoint.
Beyond functional preservation, chronic hexarelin administration produced measurable anti-fibrotic effects. Treated mice showed significant reductions in left ventricular mass, interstitial collagen deposition, and total collagen concentration at 21 days. The molecular mechanism underlying these anti-fibrotic effects involved suppression of TGF-beta1 expression and reduced myofibroblast differentiation, the cellular process responsible for pathological collagen overproduction in injured myocardium.
A separate 2020 study by the same research group, published in Biomedicine and Pharmacotherapy, extended these findings by demonstrating that hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in ischemia-reperfusion models. This work linked hexarelin’s cardiac protection to modulation of central inflammatory signaling, suggesting the peptide’s cardioprotective mechanism may involve both direct myocardial CD36 activation and indirect neuroimmune modulation.
Earlier work examining spontaneously hypertensive rats demonstrated that chronic hexarelin administration significantly reduced both interstitial and perivascular myocardial collagen deposition, along with decreased myocardial hydroxyproline content. Published in the American Journal of Physiology: Heart and Circulatory Physiology, this study established hexarelin’s anti-fibrotic activity in a chronic hypertensive cardiomyopathy model rather than an acute ischemic injury model, broadening the potential research applications across multiple cardiac pathology paradigms.
Tachyphylaxis and Receptor Desensitization
A significant consideration in hexarelin research is the well-documented desensitization of GH release with chronic administration. In vitro studies demonstrated marked attenuation of the intracellular calcium response to hexarelin within 2 to 5 minutes of the initial dose at the second messenger level, indicating rapid homologous receptor desensitization. Rodent studies confirmed this observation in vivo, showing significant blunting of the GH response between first and second doses administered in close succession.
A 16-week clinical study documented a progressive decline in GH responsiveness: the GH response to hexarelin decreased significantly by week 4 and showed further attenuation by week 16 of continuous administration. However, receptor sensitivity returned to baseline approximately 4 weeks after discontinuation, indicating that the desensitization is reversible and likely mediated by GHS-R1a internalization and downregulation rather than permanent receptor modification. This temporal recovery profile has informed the design of intermittent dosing protocols in subsequent research studies.
Importantly, the tachyphylaxis appears specific to the GHS-R1a/GH axis. The CD36-mediated cardioprotective effects have not shown comparable desensitization in chronic administration models, which aligns with the mechanistic independence of the two receptor pathways. This divergence further supports the concept that hexarelin’s cardiac and endocrine activities are pharmacologically separable.
Comparative Positioning Among Growth Hormone Secretagogues
Within the GH secretagogue family, hexarelin occupies a specific pharmacological niche defined by maximal GH-releasing potency coupled with significant off-target hormonal effects. At equivalent molar doses, hexarelin produces GH pulses of greater magnitude than GHRP-6 or GHRP-2. However, this potency comes with concurrent stimulation of ACTH, cortisol, and prolactin secretion that exceeds what is observed with more selective GHRPs.
Ipamorelin represents the opposite end of the selectivity spectrum. While producing lower peak GH levels than hexarelin, ipamorelin achieves GH release without measurable effects on cortisol, prolactin, or appetite, making it the most receptor-selective GH secretagogue available for research. GHRP-2 falls between these two extremes, offering strong GH stimulation with moderate and dose-dependent cortisol and prolactin elevation.
The critical differentiator for hexarelin, however, is not its position on the GH potency/selectivity spectrum but rather its unique CD36 engagement. No other synthetic GH secretagogue has demonstrated the same degree of CD36-mediated cardioprotective activity. Small-molecule GHS-R1a agonists such as MK-0677 (ibutamoren) and EP51389 were unable to compete with hexarelin for CD36 binding in receptor competition assays, indicating that this interaction is structurally specific to hexarelin’s peptide architecture rather than a general property of GHS-R1a ligands.
Key Research Findings
- Hexarelin binds GHS-R1a with 10 to 20-fold greater affinity than native ghrelin, producing the largest acute GH pulses of any synthetic GHRP tested in head-to-head comparisons
- CD36 knockout mice showed complete loss of hexarelin’s cardioprotective effect while GHS-R1a knockouts retained full cardiac protection, proving GH-independent cardioprotection (Bhatt et al., Circulation Research, 2004)
- In mouse MI models, hexarelin at 0.3 mg/kg/day for 21 days significantly improved LV function by day 14 and reduced interstitial collagen, TGF-beta1 expression, and myofibroblast differentiation (McDonald et al., Physiological Reports, 2018)
- Hexarelin and GHRP-2 produced ACTH/cortisol elevations comparable to hCRH and prolactin release lower than TRH in healthy adults, confirming multi-hormone activation (Arvat et al., Peptides, 1997)
- GH-axis tachyphylaxis develops by week 4 of continuous administration but reverses within 4 weeks of discontinuation, while CD36-mediated effects do not show comparable desensitization
- In rat pituitary cell cultures, hexarelin at 1 micromolar stimulated GH release to 185 +/- 23% of control in normal cells and 155 +/- 25% in GHRH-insensitive GH1 cells
Research Applications and Methodological Considerations
Hexarelin serves dual roles as a research tool. In neuroendocrine investigation, it functions as a potent GHS-R1a agonist for studying growth hormone axis regulation, receptor desensitization kinetics, and the interaction between GHRP and GHRH signaling pathways. In cardiovascular research, it provides a pharmacological probe for CD36-mediated cardioprotective signaling, enabling investigation of PI3K/Akt, ERK1/2, and anti-apoptotic pathways in myocardial ischemia-reperfusion models.
Researchers working with hexarelin should note several methodological considerations. The peptide’s desensitization profile requires careful attention to dosing frequency and study duration when GH endpoints are of primary interest. Concurrent measurement of prolactin, ACTH, and cortisol alongside GH is recommended to fully characterize the endocrine response profile. For cardiac studies, the use of CD36 knockout or GHS-R1a knockout controls remains the gold standard for pathway attribution. Storage should follow standard peptide handling protocols: lyophilized powder at -20C long-term, reconstituted solutions at 2 to 8C for short-term use, with protection from light and repeated freeze-thaw cycles.
The molecular formula is C47H58N12O6, the molecular weight is 887.04 g/mol, and the CAS number is 140703-51-1. Research-grade hexarelin is typically supplied as a lyophilized powder at purity levels of 98% or higher as determined by HPLC analysis, with identity confirmation via mass spectrometry.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Maple Research Labs provides research-grade peptides with independent third-party Certificate of Analysis verification through Janoshik Analytical. Explore our full catalog of research peptides, including related GH secretagogues like Ipamorelin and CJC-1295 DAC. For a comparative overview of the GH secretagogue class, see our research guide on Growth Hormone Secretagogues Compared. Learn more about how we verify peptide identity and purity in our guide to reading a Certificate of Analysis.
Want more research like this?
Weekly peptide study breakdowns. No spam. Unsubscribe anytime.